Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention DCS Lab, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.8 for the same window.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention DCS Lab, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.8 for the same window. At 6, the average consequence score sits below the same-window beat average of 6.4. Multi-omics appears in 1 tracked Biotech story from March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Multi-omics. Shared-story counts are live from our verified record — not editorial picks.
Infrastructure Deployment
Installation of DNBSEQ-T7 and spatial transcriptomics platforms at NUS.
Partnership Announcement
MGI Tech and NUS officially announce the collaboration to build the DCS Lab.
Research Commencement
Launch of the first joint multi-omics projects focused on pharmaceutical innovation.
MGI Tech and the National University of Singapore (NUS) have announced a strategic collaboration to establish a DCS Lab focused on multi-omics innovation. The facility will leverage MGI's advanced sequencing technologies to accelerate drug discovery and pharmaceutical research in the APAC region.
Multi-omics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
